Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III multicenter randomized double-blind controlled study of recombinant Mycobacterium tuberculosis fusion protein (EC) for tuberculosis infection diagnosis in adults aged 65 years and older
CTR20231121Phase 3Active
- Sponsor
- Anhui Zhifei Longcom Biopharmaceutical
- Start
- Aug 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of C-Tb in Tuberculosis (TB), sponsored by Anhui Zhifei Longcom Biopharmaceutical. Started Aug 2023; status: active.
02
Drugs
C-Tb
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on CTR20231121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231121.